Mutation Analysis in Chronic Myeloid Leukemia Patient in Chronic Phase on Imatinib Having Delayed Achievement of Milestones or Loss of Response
- 105 Downloads
Tyrosine kinase inhibitors (TKI’s) are currently the drug of choice for management of chronic myeloid leukemia. Imatinib is the most commonly used first line TKI in India. Mutations leading to resistance to imatinib are the most common cause for imatinib failure. We studied pattern of kinase domain mutations in 40 patients of CML who either lost their response or did not achieve it in defined timepoints. Loss of molecular response was the most common indication for asking mutation analysis. Sixteen patients were found to have detectable mutations. M351T was the most common tyrosine kinase mutation followed by Y253H and H396R. Two patients had 2 mutations simultaneously. M351T is the most common mutation in our patient population.
KeywordsTyrosine kinase inhibitors Imatinib Kinase domain mutations Molecular response
Compliance with Ethical Standards
Conflict of interest
All authors declared no conflict of interest.
All procedures performed in this study were in accordance with the ethical standards of the institution and with the 1964 Helsinki’s Declaration.
Informed Consent Statement
Informed consent was obtained for all individuals participating in this study.
- 6.Kantarjian H, Hochhaus A, Saglio G, Souza C, Flinn I, Stenke L et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841–851CrossRefPubMedGoogle Scholar
- 9.Soverini S, Hochhaus A, Nicolini FE, Franz G, Lange T, Saglio G et al (2011) BCR–ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European leukemiaNet. Blood 118(5):1208–1215CrossRefPubMedGoogle Scholar
- 11.Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al (2006) Contribution of ABL kinase domain mutations in imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA working party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374–7379CrossRefPubMedGoogle Scholar
- 12.Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al (2003) Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate binding loop(p-loop) are associated with poor prognosis. Blood 102:276–283CrossRefPubMedGoogle Scholar
- 14.Prabhash K, Vora T, Chadyalpatil NS et al (2009) Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia patients on imatinib at the time of loss of response to the drug in Asian Indian subjects. J Clin Oncol 27:7079Google Scholar